Infectious Diseases Pharmacotherapy Residency University of Kentucky Chandler Medical Center
PharmD Univ Of Kentucky
Director, Practice and Residency Advancement
Dr. Craig Martin
Dr. Martin serves in a joint role as Director of Professional Practice Development for both UK College of Pharmacy and UK HealthCare Pharmacy Services. In this role he develops and oversees clinical practice sites for College of Pharmacy faculty, serves as administrative director for UK Pharmacy Residencies, and leads professional development initiatives for UK HealthCare pharmacy staff. As a Board Certified Pharmacotherapy Specialist with Added Qualifications in Infectious Diseases, Dr. Martin remains active in the clinical arena by working with UK HealthCare’s Infectious Diseases Division and Infection Prevention and Control staff. Since 2002, he has helped lead the nationally-recognized UK HealthCare Antimicrobial Stewardship Program.
Dr. Martin is a recipient of American Society of Health-System Pharmacists’ “Best Practice Award” for 2004 as well as the Society of Infectious Diseases Pharmacists’ “Outstanding Clinical Practice in Infectious Diseases Pharmacotherapy” award for 2005 and the Kentucky Society of Health Systems Pharmacists’ “Pharmacist of the Year” award for 2010.
A native Kentuckian, Dr. Craig Martin received his Doctor of Pharmacy degree from the University of Kentucky College of Pharmacy in 1999 and completed an Infectious Diseases Specialty Residency at UK in 2002.
Crass Ryan L, Rutter W Cliff, Burgess Donna R, Martin Craig A, Burgess David S, Array Array. (2016). Comparative Nephrotoxicity of Polymyxin B and Colistimethate Sodium in Patients with Cystic Fibrosis.IDWeek 2016,
Cady Elizabeth, Rutter W Cliff, Burgess Donna R, Kincaid Scott, Martin Craig A, Burgess David S. (2016). Utilizing Nanosphere's Verigene® Technology to Assist with Possible Rapid Pharmacologic De-escalation of Antimicrobial Therapy In A University Hospital Setting.IDWeek 2016,
Cotner Sarah, Rutter W Cliff, Burgess Donna R, Martin Craig A, Burgess David S, Array Array. (2016). Influence of Beta-lactam Infusion Strategy on Acute Kidney Injury.IDWeek 2016,
Mediwala Krutika N, Rutter W Cliff, Burgess Donna R, Martin Craig A, Wallace Katie, Burgess David S. (2016). Risk Factors for Pseudomonas aeruginosa to Guide Empiric Therapy for Gram-negative Infections.American College of Clinical Pharmacy,
Crass Ryan L, Rutter W Cliff, Burgess Donna R, Martin Craig A, Burgess David S. (2016). Development of Acute Kidney Injury in Patients treated with Polymyxin B Compared to Colistimethate Sodium.IDWeek 2016,
Thompson R Zachary, Martin Craig A, Burgess Donna R, Rutter W Cliff, Burgess David S, Array Array. (2016). Optimizing Beta-Lactam Pharmacodynamics against Pseudomonas aeruginosa in Adult Cystic Fibrosis Patients.Journal of Cystic Fibrosis, 15(5), 660-663.
Flannery Alexander H, Martin Craig A, Cook Aaron M. (2016). Antimicrobial dosing in obesity.American Society of Health-System Pharmacists,
Thompson Robert Z, Martin Craig A, Burgess Donna R, Burgess David S. (2015). Optimizing Beta-Lactam Pharmacodynamics in Adult Cystic Fibrosis Patients Utilizing Local Susceptibilities.ID Week 2015,
Array Array, Cox Jessica, Rutter W Cliff, Martin Craig A, Burgess Donna R, Zephyr Dominique, Burgess David S. (2015). Acute Kidney Injury During Therapy with Vancomycin in Combination with Beta-Lactams.ID Week 2015,
Array Array, Bachmeier Harrison, Ereshefsky Benjamin, Feola David J, Martin Craig A, Burgess David S. (2015). Pharmacokinetic and Pharmacodynamics (PK/PD) of Piperacillin (PIP) in Patients on Intermittent Hemodialysis (HD).ID Week 2015,